Summary by Moomoo AI
NeuroSense Therapeutics Ltd., a biotechnology firm specializing in treatments for neurodegenerative diseases, announced on October 9, 2024, its plans to file for early commercialization of its ALS treatment, PrimeC, in Canada under Health Canada's NOC/c policy. This decision follows positive results from the Phase 2b ALS PARADIGM clinical trial, which showed a 36% reduction in disease progression and a 43% improvement in survival rates compared to placebo. CEO Alon Ben-Noon expressed optimism for the potential of PrimeC to meet the urgent needs in ALS treatment. The company also plans to seek approval in additional countries. PrimeC has been designed to target multiple key mechanisms of ALS and has been granted Orphan Drug Designation in the U.S. and EU. The PARADIGM trial, which included participants from Canada, Italy, and Israel, demonstrated significant efficacy of PrimeC, with most participants opting to continue treatment post-trial. NeuroSense is committed to advancing regulatory approvals to expedite access to PrimeC for ALS patients.
